Background and Purpose-Guidelines recommend dual antiplatelet treatment with ticagrelor instead of clopidogrel after acute myocardial infarction. Ticagrelor increases major and minor noncoronary artery bypass graft bleeding compared with clopidogrel, but whether the risk of intracranial hemorrhage (ICH) increases is unknown. We aimed to examine any association between ticagrelor and ICH and to identify predictors of ICH among unselected patients after acute myocardial infarction. Methods-Patients with acute myocardial infarction were identified using the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions, and the data were combined with the Swedish National Patient Registry to identify ICH occurrence. To avoid obvious selection bias related to the choice of dual antiplatelet treatment, we divided the study cohorts into 2 time periods of similar length using the first prescription of ticagrelor as a cutoff point (December 20, 2011). The risk of ICH during the first period (100% clopidogrel treatment) versus the second period (52.1% ticagrelor and 47.8% clopidogrel treatment) was assessed using Kaplan-Meier analysis. Cox proportional-hazards regression analyses, with assessment of interactions between all significant variables, were used to identify predictors of ICH. In multivariable Cox analysis, study period (second versus first period) was not predictive of ICH. Interaction analyses showed that age and prior cardiovascular morbidities were of importance in predicting the risk of ICH. Conclusions-The increased use of ticagrelor was not associated with ICH, whereas age and prior cardiovascular morbidities were related to the risk of ICH and interacted significantly.
M ore potent platelet inhibitors decrease the risk of major vascular events after an acute myocardial infarction (AMI) but also increase the risk of bleeding. Bleeding events in patients with AMI are associated with poor prognosis and increased mortality. 1 Since 2011, the standard antithrombotic therapy after AMI in Sweden is the combination of aspirin and the P2Y12 inhibitor, ticagrelor, in line with international recommendations based on the PLATO trial (Platelet Inhibition and Patient Outcomes). 2 Overall, there was no difference in total major or fatal bleeding events, but noncoronary artery bypass graft major bleeding was more common in ticagrelor-treated patients. Intracranial hemorrhage (ICH) was uncommon, but there were more fatal ICH events in ticagrelor-than clopidogrel-treated patients (11 versus 1) . Because of the small number of events, these data and the ICH data from a recent randomized study were inconclusive. 3, 4 A recent, large observational study of patients with acute coronary syndrome showed no increase in major bleeding or ICH in ticagrelor-compared with clopidogrel-treated patients, but patients treated with ticagrelor were healthier and had fewer comorbidities, making the results inconclusive. 5 In randomized trials, a selection bias when patients are recruited is common, resulting in a study population with younger ages and fewer comorbidities compared with real life. In observational studies comparing ticagrelor and clopidogrel treatment, selection bias resulted in considerable differences between the 2 cohorts. 5, 6 Consequently, there is a knowledge gap about the effect of ticagrelor on the risk of
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ICH in an unselected population with fairly equal baseline data compared with a clopidogrel-treated cohort. We, therefore, aimed to investigate the impact of a change in treatment regimen from clopidogrel to ticagrelor on the incidence of ICH in patients after AMI using 2 consecutive and unselected cohorts and, furthermore, to identify predictors of ICH.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
The study population was obtained from the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies, which is a national quality register launched in 2009 after merging 4 established registers, including the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Details about the register have been described previously. 7 Patients presenting with AMI who were hospitalized in a coronary care unit are included in the RIKS-HIA register. No exclusion criteria exist. All participating hospitals use standardized and identical criteria to define AMI. 8 Patient data are collected on case record forms that include >100 variables, including information about patient characteristics, diagnosis, medication, and procedures that are recorded on admission, during the patient's hospital stay, and at discharge. The validity of the data entered is evaluated annually, and 94% to 97% conformity between RIKS-HIA records and patient records has been demonstrated.
To identify cases in which ICH occurred after AMI, the RIKS-HIA database was amalgamated with the Swedish National Patient Register (NPR). The NPR has had complete national coverage since 1987 and it contains diagnoses at discharge for all hospital stays in Sweden. A full description of the registry has been published previously. 9 Diagnoses are recorded in the NPR using codes defined by the Swedish International Classification of Diseases, which was adapted from the World Health Organization International Classification of Diseases classification system. ICH cases were identified in the registry by searches for the following codes from the 10th Revision of the International Classification of Diseases; subarachnoid hemorrhage (I60), intracerebral hemorrhage (I61), and other nontraumatic ICH (I62). The NPR lacks information about the principal diagnosis for 0.5% to 0.9% of somatic care-related hospitalizations. A diagnosis of stroke or transient ischemic attack in the NPR was determined to be correct in 98.6% of the cases, and the proportion of stroke events identified ranges from 84.2% to 98% as shown by validation studies. 9, 10 No published studies have specifically validated the diagnosis of ICH in the NPR; however, the validity is expected to be at least as good as that of the diagnosis of ischemic stroke because the diagnosis of ICH can only be made after a positive computed tomographic scan, magnetic resonance tomographic scan, or at autopsy.
Ethical Considerations
The National Board of Health and Welfare and the Swedish Data Inspection Board approved the RIKS-HIA register. The regional ethics committee in Stockholm approved merging of the registries.
Study Design
The use of ticagrelor began at the end of 2011 and was preferably chosen for patients with low bleeding risk, younger age, and fewer comorbidities. To avoid selection bias between patients treated with clopidogrel and ticagrelor, we used the first prescription of ticagrelor as a cutoff point (December 20, 2011) , and the study period was divided into 2 time periods of similar length to create 2 cohorts. The first time period was from December 8, 2009 , to December 19, 2011 , and the second time period was from December 20, 2011, to December 31, 2013. In the early cohort created from the first time period, all patients received clopidogrel, whereas in the later cohort created from the second time period, patients were treated with either clopidogrel or ticagrelor. The use of ticagrelor rapidly increased during the second study period, and the impact of ticagrelor on the second time period is based on >50% of the patients being treated with ticagrelor.
Certain variables from the RIKS-HIA register have been redefined before data analysis. The variable smoking was defined as smoking during the past month. The variable atrial fibrillation was defined as previous atrial fibrillation or atrial fibrillation during hospitalization. Heart failure during hospitalization includes patients either receiving treatment with intravenous diuretics or patients with clinical signs of heart failure, such as pulmonary rales during hospitalization. The variable estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
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Statistical Analysis
The clinical characteristics and medications at admission and discharge were extracted from the amalgamated database. Statistical results are presented as the median with 25th and 75th percentiles for continuous variables and as percentages for categorical variables. Data for patients in the early versus later study periods were compared with the Mann-Whitney U test for continuous variables and with the Pearson χ 2 test for categorical variables. Kaplan-Meier analyses were used to estimate the cumulative incidence of ICH in the early and late time period cohorts, with comparisons between cohorts by the log-rank test. A P value <0.05 was considered significant.
A multivariable Cox proportional-hazards regression model was used to identify predictors of ICH. Variables included in the multivariable Cox regression analysis had previously been described as risk factors or were of potential importance. Nonsignificant variables were excluded stepwise according to their level of significance during subsequent runs of the multivariable Cox regression analysis, until reaching only significant predictors. However, because the remaining variables are likely to interact with each other, a final model was formed with interactions between all variables. Sex was included regardless of significance level. The assumption of proportional hazards was verified using scaled Schoenfeld residuals. Results are presented as hazard ratios with 95% CIs.
Statistical analyses were performed using SPSS (version 23.0; IBM Corp, Armonk, NY) and SAS software (version 9.4; SAS Institute, Inc, Cary, NC).
Results
During the study period, 47 674 patients were included. The first period comprised 23 447 patients treated with clopidogrel only. The later period comprised 24 227 patients treated with either clopidogrel (47.8%) or ticagrelor (52.1%).
During the later period, the use of ticagrelor increased rapidly, and at the end of the period, 67.8% of the patients were prescribed ticagrelor.
Baseline Characteristics
Baseline characteristics are shown in Table 1 . The early and the late cohorts had fairly equal baseline data. Hypertension, revascularization with percutaneous coronary intervention, coronary artery bypass graft, and previous peripheral arterial disease were slightly more prevalent in the late cohort. On the contrary, previous myocardial infarction (MI), thrombolysis during hospitalization, heart failure during hospitalization, and smoking history were more prevalent in the early cohort.
The distribution of age, sex, ST-segment-elevation myocardial infarction (STEMI), previous ischemic stroke, diabetes, previous dialysis, estimated glomerular filtration rate, previous ICH, and atrial fibrillation did not differ between the cohorts. Table 2 shows medications at discharge in the early and late cohorts. Patients in the early cohort were more often treated with aspirin (dose, 75 mg daily), β-blockers, and diuretics, whereas patients in the late cohort were more often treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, oral anticoagulants, and calcium blockers. There was no difference between groups regarding statin treatment. For medication at admission, see Table I in the online-only Data Supplement. In the late cohort we found patients treated with ticagrelor to be healthier with less risk factors compared with patients treated with clopidogrel, see Table II in the online-only Data Supplement. Table  III in the online-only Data Supplement shows medication at discharge in clopidogrel-and ticagrelor-treated patients in the late cohort.
Incidence and Time Trends
The cumulative incidence of ICH during the first period was 0.59% (n=91; 95% CI, 0.49-0.69) versus 0.52% (n=97; 95% CI, 0.43-0.61) during the second period (P=0.83; Figure) . The corresponding 1-year cumulative incidences were 0.41% (n=77; 95% CI, 0.33-0.49) and 0.48% (n=90; 95% CI, 0.39-0.57), respectively (P=0.83).
The 1-year cumulative incidence of all-cause death was similar; 8.2% (95% CI, 7.85-8.55) during the first period and 8.4% (95% CI, 8.05-8.55) during the second period (P=0.82). Of the 188 patients with an ICH (first period, n=91; second period, n=97), 30% had a STEMI and 68% a non-STEMI. Table 3 shows the significant results from the final multivariable Cox regression model, with analyses of interactions between all variables. Age (dichotomized), previous MI, previous ischemic stroke, and, particularly, previous hemorrhagic stroke were of importance for predicting the risk of ICH. A previous MI was only significant in patients aged <75 years. A previous ischemic stroke was of importance in both age categories if no previous hemorrhagic stroke had occurred. A previous hemorrhagic stroke was of importance regardless of age category and previous ischemic stroke but increased the risk of ICH dramatically in patients aged <75 years with no prior cardiovascular event (hazard ratio, 37.3; 95% CI, 20.4-68.1). Study cohort (early or late) did not predict ICH. In the early cohort, 100% of patients were treated with clopidogrel. In the late cohort, 47.9% were treated with clopidogrel and 51.2% with ticagrelor. ACE indicates angiotensin-converting enzyme; and ARB, angiotensin receptor blocker. 
Predictors of Risk
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Discussion
The increased use of ticagrelor during the second time period (late cohort) was not associated with an increased risk of ICH. Furthermore, the shape of the Kaplan-Meier curves was similar between cohorts, and membership in the late cohort did not predict ICH in the adjusted Cox model. Age, previous ischemic stroke, and, particularly, hemorrhagic stroke were of importance for predicting the risk of ICH. None of the medications included in the analyses were associated with an increased risk.
Patients treated with ticagrelor are typically younger and have fewer comorbidities than those treated with clopidogrel (Table II in the online-only Data Supplement). To avoid this selection bias, we divided patients into 2 consecutive time periods, where ticagrelor impacted the latter period. This design resulted in 2 cohorts with similar baseline characteristics. The cumulative incidence of death did not differ between the 2 cohorts, indicating a similar overall comorbidity in the early and late cohorts, corresponding to the findings at baseline.
The present results add to the conclusions from the PLATO trial by showing that ticagrelor is not associated with an increased risk of ICH in an unselected AMI population. 2 In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared With Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), longterm treatment with ticagrelor post-AMI (1-3 years) significantly increased the rate of thrombolysis in MI major bleeding, but the rates of ICH were low and similar across the study groups (3-year incidence: 0.56%, 0.61%, and 0.42% in the ticagrelor 90 mg orally BID, 60 mg orally BID and placebo groups, respectively). However, the PEGASUS trial (Placebo on a Background of Aspirin) included a patient group that was at low risk of bleeding. The mean age was 65 years, the proportion of patients with STEMI was high (52%), and patients with recent bleeding, prior stroke, or need for oral anticoagulant therapy were excluded. 12 Therefore, the present data fills a knowledge gap on the safety profile of ticagrelor in populations at higher risk of bleeding.
Other studies with different designs and patient populations have found a similar risk of ICH between ticagrelor and clopidogrel. The TREAT trial (Ticagrelor in Patients With ST-Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis)-a randomized trial of patients with STEMI treated with thrombolysis-found an incidence of ICH at 30 days of 0.42% (n=8) and 0.37% (n=7) in ticagrelor-versus clopidogrel-treated patients, respectively. 4 Patients aged >75 years were excluded, and, as in PLATO, the mean age was low (58 years). 4 A recent large observational study of patients with acute coronary syndrome in Taiwan found no association between increased major bleeding and ticagrelor compared with clopidogrel and no increased risk of ICH. Notably, because of obvious differences in baseline characteristics, propensity score matching was used. After statistical adjustment, the 3-year ICH incidence was 0.3% (7 of 2389) for ticagrelor-versus 0.4% (81 of 19112) for clopidogrel-treated patients. 5 These study populations were at low risk of ICH, and the number of ICH events in ticagrelortreated patients was low.
The occurrence of ICH within 1 year of admission in the present study was similar to the corresponding 1 year occurrence from discharge found in clopidogrel-treated patients (and >90% on aspirin treatment) in an earlier study using Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies data from 2005 to 2010 (169 of 65483; 0.3%). 13 Consistent with previous studies, a history of hemorrhagic stroke was associated with the highest risk of ICH. 3, 13, 14 A history of MI and ischemic stroke, as well as age, was also of importance in predicting the risk of ICH. [13] [14] [15] [16] Predictors of ICH may influence each other; therefore, we analyzed interactions between all variables. We found that a previous MI was related to an increased risk of ICH in patients <75 years of age, but in the elderly, the impact of a previous MI was not significant. Similarly, in patients >75 years of age, previous cerebrovascular events were of less importance in predicting ICH than in younger patients. Older age per se was a risk factor for ICH, which reduced the importance of prior cardiovascular events to predict ICH in the age category >75 years (Table 3) . Because of the limited number of outcome events, the CIs are wide in some cases.
We did not find female sex to increase the risk of hemorrhage as seen in some previous studies, but these were short-term studies with an end point of major bleeding, 17, 18 not ICH, or were thrombolysis studies 19, 20 and thus are not comparable. In contrast, a previous study from the Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry found a decreased long-term ICH risk in women. 13 Decreased 21 ), and a subgroup study from PLATO found no difference between women and men in terms of bleeding risk. 22 Women may be more vulnerable during the acute stage after AMI and more sensitive to medication and doses of antithrombotics, but in the long term, comorbidity seems to have a higher impact on bleeding risk than sex.
Strengths and Limitations
A strength of this study was the large size of the study cohorts and the unselected inclusion criteria. However, this was an observational study, and selection bias is unavoidable. We did not directly compare ticagrelor with clopidogrel because of obvious selection bias related to the choice of therapy. Instead, we compared 2 time periods where ticagrelor impacted the latter period.
Since 2004, all patients with AMI, regardless of the level of care, are expected to be included in the registry, not just patients in a coronary care unit. However, elderly patients with extensive comorbidities may not be included, which can lead to an underestimation of the ICH rate because, based on previous studies and our present results, older patients are expected to have a higher risk of ICH than younger ones.
Furthermore, when trying to identify predictor variables in a multivariable model, there is always the risk of confounding factors that are not taken into account because they were not recorded as variables in the database. Significant variables that may affect each other were analyzed for interaction in the final model.
Conclusions
The increased use of ticagrelor was not associated with ICH. Age, previous MI, and previous ischemic and, particularly, previous hemorrhagic stroke influenced ICH risk with significant interactions.
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